A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

Launched by PHARMACIA · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Zidovudine (AZT).
• • Didanosine (ddI).
• Patients must have the following:
• • Diagnosis of AIDS as defined by the CDC.
• • Blood cultures positive for Mycobacterium avium complex or for acid-fast bacilli (AFB).
• • Provide written informed consent.
• Prior Medication:
• Allowed:
• • If receiving zidovudine (AZT) or ddI must be taking the medication for at least 4 weeks prior to study entry.
• * Required:
• • Antipneumocystis prophylactic therapy for at least 4 weeks prior to study entry.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• • Known hypersensitivity to any of the study drugs.
• Concurrent Medication:
• Excluded:
• • Other therapy for mycobacterial disease.
• Patients with the following are excluded:
• • Known hypersensitivity to any of the study drugs.
• Prior Medication:
• Excluded within 4 weeks:
• • Therapy for mycobacterial disease.
• • Antiretroviral drugs, other than zidovudine (AZT) or ddI.
• • Investigational drugs, other than ddI.